Reimbursement Achievable for Biologics in Psoriasis

September 1, 2003

The January FDA clearance of Biogen Inc.'s Amevive (alefacept) for the treatment of moderate-to-severe chronic plaque psoriasis officially ushered in the era of biologic treatments for dermatologists.

Related Content:

Practice Management